CRDL:CC News and Press, Cardiol Therapeutics Inc. From 05/18/22

Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation . Here we discuss the FDA’s Orphan Drug Designation pro...

Third IND authorization for CardiolRx™ in cardiovascular disease Study to run in parallel with Company's multi-national Phase II acute myocarditis trial, expected to commence imminently CardiolRx™ is now eligible for orphan drug status in two indications Oakville, Ont...

Palm Beach, FL – May 11, 2022 – FinancialNewsMedia.com News Commentary – Diabetes and heart failure are closely linked . People with type 2 diabetes are two to four times more likely to develop heart failure than someone without diabetes. Heart failure i...

Expanded the Phase II/III LANCER clinical trial in patients with cardiovascular disease (CVD), or significant CVD risk factors, who are hospitalized with COVID-19 Received authorization from the FDA to proceed with the Company's IND to commence a Phase II multi-national clinical t...

Oakville, Ontario--(Newsfile Corp. - March 22, 2022) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiova...

Oakville, Ontario--(Newsfile Corp. - March 15, 2022) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiova...